CN116322764A - 因子xii抗原结合蛋白的高浓度制剂 - Google Patents

因子xii抗原结合蛋白的高浓度制剂 Download PDF

Info

Publication number
CN116322764A
CN116322764A CN202180053399.8A CN202180053399A CN116322764A CN 116322764 A CN116322764 A CN 116322764A CN 202180053399 A CN202180053399 A CN 202180053399A CN 116322764 A CN116322764 A CN 116322764A
Authority
CN
China
Prior art keywords
formulation
seq
protein
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180053399.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·约翰斯顿
D·G·古德奥
N·A·爱德华兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiete Innovation Co ltd
Original Assignee
Jiete Innovation Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiete Innovation Co ltd filed Critical Jiete Innovation Co ltd
Publication of CN116322764A publication Critical patent/CN116322764A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180053399.8A 2020-07-03 2021-07-05 因子xii抗原结合蛋白的高浓度制剂 Pending CN116322764A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20184004.8 2020-07-03
EP20184004 2020-07-03
PCT/AU2021/050714 WO2022000046A1 (en) 2020-07-03 2021-07-05 High concentration formulation of factor xii antigen binding proteins

Publications (1)

Publication Number Publication Date
CN116322764A true CN116322764A (zh) 2023-06-23

Family

ID=71514949

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180053399.8A Pending CN116322764A (zh) 2020-07-03 2021-07-05 因子xii抗原结合蛋白的高浓度制剂

Country Status (12)

Country Link
US (1) US20240277839A1 (enExample)
EP (1) EP4175669A4 (enExample)
JP (1) JP7880827B2 (enExample)
KR (1) KR20230035355A (enExample)
CN (1) CN116322764A (enExample)
AU (1) AU2021302684A1 (enExample)
BR (1) BR112022026482A2 (enExample)
CA (1) CA3183508A1 (enExample)
CL (1) CL2023000004A1 (enExample)
IL (1) IL298989A (enExample)
MX (1) MX2022016365A (enExample)
WO (1) WO2022000046A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4337257A1 (en) * 2021-05-12 2024-03-20 AnaptysBio, Inc. Antibody composition
US20250042984A1 (en) * 2021-12-20 2025-02-06 CSL Innovation Pty Ltd Protein formulations and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250164T1 (hr) 2011-07-22 2025-04-11 Csl Behring Gmbh Inhibitorna monoklonska antitijela protiv faktora xii/xiia i njihove uporabe
JP5859148B2 (ja) * 2012-03-08 2016-02-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ａβ抗体製剤
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
EP3325516B1 (en) * 2015-07-21 2021-12-15 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor xiia
EP3433274A1 (en) * 2016-03-25 2019-01-30 Visterra, Inc. Formulation of antibody molecules to dengue virus
EP3440107A4 (en) * 2016-04-06 2020-02-19 CSL Limited METHOD FOR TREATING ATHEROSCLEROSIS
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
BR112019011900A2 (pt) 2016-12-23 2019-11-26 Serum Institute Of India Private Limited métodos melhorados para aumentar a produtividade de anticorpos na cultura de células de mamíferos e minimizar a agregação durante os processos downs-tream, processos de formulação, e formulações de anticorpos estáveis obtidas dos mesmos
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
EA202190056A1 (ru) * 2018-06-19 2021-05-28 Ридженерон Фармасьютикалз, Инк. АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ
US12134657B2 (en) 2018-11-28 2024-11-05 Oregon Health & Science University Therapeutic factor XII antibody
US20230390418A1 (en) * 2020-10-29 2023-12-07 Regenxbio Inc. Vectorized factor xii antibodies and administration thereof

Also Published As

Publication number Publication date
WO2022000046A1 (en) 2022-01-06
CA3183508A1 (en) 2022-01-06
KR20230035355A (ko) 2023-03-13
CL2023000004A1 (es) 2023-08-25
AU2021302684A1 (en) 2023-02-23
EP4175669A1 (en) 2023-05-10
BR112022026482A2 (pt) 2023-01-31
JP7880827B2 (ja) 2026-06-26
MX2022016365A (es) 2023-01-30
US20240277839A1 (en) 2024-08-22
EP4175669A4 (en) 2025-11-12
JP2023531315A (ja) 2023-07-21
IL298989A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
US20240398914A1 (en) Combination therapy using a factor xii inhibitor and a c-1 inhibitor
TWI761869B (zh) 包含抗cd47/pd-l1雙特異性抗體的製劑及其製備方法和用途
JP6920393B2 (ja) 抗体製剤
CN107635581A (zh) 用于单克隆抗体的稳定液体制剂
WO2012168491A1 (en) Pharmaceutical formulations of pcsk9 antagonists
US20220017638A1 (en) Method of treating atherosclerosis
JP2023554087A (ja) タンパク質製剤及びその使用
KR20230035355A (ko) 인자 xii 항원 결합 단백질의 고농도 제형
JP7509787B2 (ja) 抗血栓症作用および抗炎症作用を有する、第ｘｉ因子に対する新規ヒト化抗体およびその使用
KR20230020449A (ko) 레빌리맙의 수성 약학적 조성물
EP4461749A1 (en) Pharmaceutical composition comprising anti-fxi/fxia antibody and use thereof
TW202541841A (zh) 用於治療ｃ１ｓ介導病症的包含抗體的醫藥組成物及其使用方法
JP2024544058A (ja) 抗葉酸受容体コンジュゲートがん治療法
HK1220132B (en) Combination therapy using a factor xii inhibitor and a c1-inhibitor
HK1238532A1 (en) Antibody formulations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination